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ABSTRACT
Objectives: To evaluate the effect of baricitinib on
patient-reported outcomes (PROs) in patients with
active rheumatoid arthritis (RA) and an inadequate
response or intolerance to conventional synthetic
disease-modifying antirheumatic drugs.
Methods: In this phase III study, patients were
randomised 1:1:1 to placebo (N=228), baricitinib 2 mg
once daily (QD, N=229) or baricitinib 4 mg QD
(N=227). PROs included the Health Assessment
Questionnaire-Disability Index (HAQ-DI), Patient’s
Global Assessment of Disease Activity (PtGA), patient’s
assessment of pain, measures from patient electronic
daily diaries (duration and severity of morning joint
stiffness (MJS), Worst Tiredness, Worst Joint Pain),
Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F), SF-36, EuroQol 5-D index scores
and visual analogue scales (VAS) and the Work
Productivity and Activity Impairment Questionnaire-RA.
The primary time point for the study was week 12.
Treatment comparisons were assessed with logistic
regression for categorical measures and analysis of
covariance for continuous variables.
Results: Statistically significant improvements were
observed for both baricitinib groups versus placebo in
HAQ-DI, PtGA, pain, daily diary measures, EuroQoL
index scores and SF-36 physical component score at
week 12 and for those measures when assessed at
week 24. Baricitinib 2 mg and baricitinib 4 mg were
statistically significantly improved versus placebo for
the EuroQoL VAS and FACIT-F, respectively, at week 24.
Conclusions: Baricitinib 2 or 4 mg provided
significant improvement versus placebo in PROs across
different domains of RA, including physical function,
MJS, fatigue, pain and quality of life.
Trial registration number: NCT01721057; Results.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, sys-
temic disease associated with inﬂammatory
Key messages
What is already known about this subject?
▸ Patient-reported outcomes are obtained directly
from patients, reflecting how they feel and func-
tion in relation to rheumatoid arthritis (RA) and
to RA therapy; this information may improve the
quality of patient care and health-related quality
of life, which is an important treatment goal.
▸ In the RA-BUILD study, baricitinib (2 or 4 mg
once daily) was associated with clinical improve-
ment and inhibition of progressive radiographic
joint damage in patients with RA and an inad-
equate response or intolerance to conventional
synthetic disease-modifying antirheumatic drugs.
What does this study add?
▸ This study describes the patient-reported
outcome (PRO) data collected in RA-BUILD and
assesses whether the overall efficacy of bariciti-
nib is reflected in clinically meaningful changes
in PROs.
▸ Once-daily baricitinib 2 or 4 mg produced sig-
nificant improvements compared with placebo in
most of the prespecified PROs, including phys-
ical function, fatigue, duration and severity of
morning joint stiffness, pain and health-related
quality of life; for some PROs, including selected
daily diary measures, baricitinib treatment with
the 4 mg dose resulted in more rapid improve-
ment compared with the 2 mg dose.
How might this impact on clinical practice?
▸ The efficacy of baricitinib is not limited to
physician-based or laboratory-based assess-
ments, but translates to a positive benefit with
respect to patients’ health-related quality of life
and overall function; the study results suggest
that baricitinib is a potentially valuable addition
to the rheumatoid arthritis treatment arsenal for
patients struggling with this common and disab-
ling condition.
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activity and joint damage that result in disability, pain
and other impairments.1–4 Subsequently, RA adversely
affects patients’ daily activities and health-related quality
of life (HRQOL),5–8 and the patient-reported burden of
RA is considered an important factor in the manage-
ment of RA.9 10
Selected patient-reported outcomes (PROs) are incor-
porated in the American College of Rheumatology
(ACR) improvement criteria and composite measures of
disease activity, such as the Disease Activity Score (DAS),
Clinical Disease Activity Index (CDAI) and Simpliﬁed
Disease Activity Index (SDAI).11 The information
obtained with these measures is useful to assess efﬁcacy,
yet is limited in assessing the range of health domains
and treatment effectiveness important to patients with
RA, such as the HRQOL, fatigue, and well-being in daily
life and in work. A number of PRO instruments have
therefore been developed to measure the physical, emo-
tional and social burden of RA. Since these PRO mea-
sures are obtained directly from the patients and are not
inﬂuenced by other individuals, they may more accurately
reﬂect how the patient feels and functions in relation to
RA and to therapy.12 13 The PRO measures also may facili-
tate doctor–patient communication and shared decision-
making to improve the quality of patient care,14 15 which is
an overarching principle recommended by EULAR.16
Baricitinib is a selective inhibitor of Janus kinase
( JAK)1/JAK2 that interrupts signalling in pathways for
several cytokines considered important in RA pathogen-
esis.17 In the Phase III RA-BUILD clinical trial, bariciti-
nib (2 or 4 mg once daily (QD)) was associated with
clinical improvement and inhibition of progression of
radiographic joint damage in patients with RA and an
inadequate response (IR) or intolerance to conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs).18 The current paper describes the PRO
data collected in RA-BUILD and assesses whether the
overall efﬁcacy of baricitinib is reﬂected in clinically
meaningful changes in PROs.
PATIENTS AND METHODS
Patients
RA-BUILD (NCT01721057) was a randomised, 24-week,
double-blind, placebo-controlled, parallel-group, inter-
national phase III study. The primary end point of the
study was the proportion of patients achieving an ACR
20% response at week 12 (baricitinib 4 mg vs placebo).
Full details of the study have been reported previously.18
Brieﬂy, patients were randomly assigned (1:1:1) to
placebo, baricitinib 2 mg or baricitinib 4 mg QD in add-
ition to any stable background therapies. Patients were
≥18 years with active RA (≥6/68 tender and ≥6/66
swollen joints; serum high-sensitivity C-reactive protein
≥3.6 mg/L (upper limit of normal 3.0 mg/L)) and an
IR (despite prior therapy) or intolerance to ≥1
csDMARDs. The use of up to two concomitant
csDMARDs was permitted, but not required, at study
entry; these must have been used for at least the preced-
ing 12 weeks with stable doses for at least the preceding
8 weeks. The study was conducted in accordance with
the ethical principles of the Declaration of Helsinki and
Good Clinical Practice guidelines and was approved by
the institutional review board or ethics committee for
each centre involved. All patients provided written
informed consent.
Methods
The PROs were prespeciﬁed secondary outcomes of
the study. Physical function was measured using the Health
Assessment Questionnaire-Disability Index (HAQ-DI).19 20
Scores range from 0 to 3, with lower scores reﬂecting
better physical function and, thus, less disability. Changes
in the HAQ-DI score were assessed in the context of a
minimum clinically important difference (MCID) of
0.22.21 Disease activity and arthritis pain were measured
using the Patient’s Global Assessment of Disease Activity
(PtGA) and patient’s assessment of pain visual analogue
scales (VAS, 0–100 mm); higher scores indicate more
disease activity or pain.
Duration of morning joint stiffness (MJS), MJS severity,
Worst Tiredness and Worst Joint Pain (referred to as
diary PROs) were collected using a daily electronic diary
from day 1 through week 12 and were key secondary
endpoints. The latter three measures were assessed with
numeric rating scales, ranging from 0 to 10, with 10
being the worst level.
Fatigue was assessed by the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F) scale (range
0 to 52), with higher scores representing less fatigue.22
For the FACIT-F, a 3–4-point change has been consid-
ered an MCID,22–24 and in this study, a value of 3.5623
was used to assess the clinical relevance of changes in
FACIT-F scores.
Health-related quality of life (HRQOL) was evaluated
using the Medical Outcomes Study (MOS) Short-Form-36
(SF-36; V.2, Acute),25 26 in which eight domains are nor-
malised (scored from 0 to 100) and are z-transformed to
calculate the physical (PCS) and mental (MCS) compo-
nent scores. An MCID of 5 was used to assess the clinical
relevance of changes in SF-36 component scores.27 28
The EuroQol 5-Dimensions (EQ-5D) Health State
Proﬁle was also used to assess HRQOL. The EQ-5D con-
sisted of two components: a descriptive system of the
respondent’s health and a rating of his/her current
health state (0–100 mm VAS), in which the end points
are labelled ‘best imaginable health state (100)’ and
‘worst imaginable health state (0)’.29 The UK and US
scoring algorithms provide an index score using the UK
or US population weighting to normalise it to that popu-
lation;30–32 index score ranged from 0 (death) to 1
(perfect health).
The Work Productivity and Activity Impairment
Questionnaire-Rheumatoid Arthritis (WPAI-RA) scale
was used to measure the health and symptoms of overall
work productivity and impairment of regular activities
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during the past 7 days. Scores are calculated as impair-
ment percentages with higher percentages indicating
greater impairment and less productivity.33
Non-diary PROs were assessed at baseline and at weeks
1, 2, 4 and every 4 weeks thereafter to week 24, with the
exceptions of the WPAI-RA (not collected at week 1)
and SF-36, EQ-5D and FACIT-F data, which were col-
lected at baseline, week 4 and then every 4 weeks until
week 24.
Statistical analyses
Randomised patients treated with ≥1 dose of the study
drug were included in the efﬁcacy analyses under a
modiﬁed intention-to-treat principle (mITT analysis set).
Treatment comparisons for categorical and continuous
efﬁcacy measures were performed using logistic regres-
sion and analysis of covariance (ANCOVA), respectively,
with baseline value (for continuous measures), treat-
ment, geographical region and centrally-conﬁrmed pres-
ence of baseline joint erosions in the model. For diary
PRO data, the ANCOVA models were based on the
average of scores collected in the 7 days prior to
the week 12 visit date without baseline adjustment for
the duration of MJS and were analysed by the non-
parametric method, Wilcoxon rank-sum test. For the
ANCOVA model, the least squares means (also consid-
ered as estimated marginal means) in each treatment
group were derived to estimate the treatment difference.
For the non-parametric method, the medians in each
treatment group were described. In post hoc analyses
evaluating the kinetics of initial effect, daily scores from
the day of randomisation (day 1) up to day 28 were also
assessed, without weekly averaging. For the daily score
analysis, mixed models for repeated measures with treat-
ment, geographical region, centrally conﬁrmed presence
of baseline joint erosions (yes/no), study day and the
interaction of treatment-by-day as covariates were
applied, with duration of MJS, analysed by non-
parametric methods using the Wilcoxon rank-sum test.
All statistical analyses were conducted using SAS V.9.2
(SAS Institute, Cary, North Carolina, USA).
Patients who were rescued or discontinued were
deﬁned thereafter as non-responders (non-responder
imputation) for all categorical efﬁcacy measures. For
continuous measures, the last observations before rescue
or discontinuation were carried forward (modiﬁed last
observation carried forward method). The WPAI-RA
measures were censored after rescue or discontinuation
without imputation applied.
For the ANCOVA analysis for continuous variables,
t-tests were performed to test the treatment differences.
For the logistic regression analyses for categorical vari-
ables, Wald tests were performed to assess treatment
comparisons. All analyses were based on a signiﬁcance
level of 0.05 (two-sided). p-Values were not adjusted for
multiple comparisons.
RESULTS
Patients
A total of 684 patients were randomised: 228 received
placebo, 229 received baricitinib 2 mg and 227 received
baricitinib 4 mg. Patient disposition has been described
in Dougados et al.18 In summary, baseline patient
characteristics and disease activity were similar among
the groups (table 1). Overall, 298 (44%), 210 (31%)
and 171 (25%) patients had previously received 1, 2 or
≥3 csDMARDs, respectively. Baseline PROs indicated a
signiﬁcant disease burden, which was consistent with the
baseline clinical disease activity (table 1).
Patient-reported outcomes
HAQ-DI, PtGA and pain
As reported in Dougados et al,18 statistically signiﬁcant
improvements compared with placebo were observed at
week 12 for HAQ-DI, PtGA and pain. Furthermore, for
baricitinib 4 mg versus placebo, statistically signiﬁcant
improvements were evident as early as week 1 for
HAQ-DI (p≤0.05 for all time points), PtGA (p≤0.01 for
all time points) and patient’s assessment of pain
(p≤0.05 for all time points). For baricitinib 2 mg, statis-
tically signiﬁcant improvements versus placebo were
observed as early as week 8 for HAQ-DI (p=0.001 for
time points after week 8), week 2 for PtGA (p≤0.05 for
time points after week 2) and week 4 for patient’s assess-
ment of pain (p≤0.01 for time points after week 4).
Signiﬁcant improvements in physical function and
reductions in PtGA and pain were maintained at weeks
12 and 24 (table 3).
The proportion of patients who met or exceeded the
MCID for HAQ-DI was 54%, 69% and 64% for placebo,
baricitinib 2 mg and baricitinib 4 mg, respectively
(p=0.001 for baricitinib 2 mg vs placebo; p=0.027 for
4 mg vs placebo) at week 12 and was 42%, 64% and
60% at week 24 (p=0.001 for both baricitinib groups vs
placebo).
Dougados et al18 also assessed treatment effect based
on background csDMARD use. A subgroup analysis with
the outcome measure, change from baseline in
HAQ-DI, suggested no heterogeneity of treatment effect
based on background csDMARD therapy (see online
supplementary table S1).
Diary PROs: duration of MJS, MJS severity, Worst Tiredness
and Worst Joint Pain
At week 12, reductions were observed in duration and
severity of MJS (table 2; for duration and severity:
p=0.002 for baricitinib 2 mg vs placebo, p=0.001 for bari-
citinib 4 mg vs placebo), Worst Tiredness (p=0.049 for
baricitinib 2 mg vs placebo, p=0.027 for baricitinib 4 mg
vs placebo) and Worst Joint Pain (p=0.001 for both bari-
citinib groups vs placebo).
With baricitinib 4 mg versus placebo, a statistically sig-
niﬁcant reduction in the severity of MJS (p≤0.05) and
in Worst Joint Pain (p≤0.01) was ﬁrst seen at week 1, in
Worst Tiredness at week 2 (p≤0.05) and in duration of
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MJS at week 4 (p≤0.05).18 With baricitinib 2 mg, the
statistically signiﬁcant (p≤0.05) reductions were ﬁrst
observed at week 8 for the duration and severity of MJS,
at week 12 for Worst Tiredness and at week 2 for Worst
Joint Pain.18
Consistent with the weekly averaged data, the daily
diary scores showed signiﬁcant improvement in patients
receiving baricitinib 2 or 4 mg compared with placebo.
The greatest rapidity and magnitude of beneﬁt was
observed with baricitinib 4 mg, with improvements
observed as early as day 3 for Worst Tiredness, day 4
for the severity of MJS and Worst Joint Pain and day 10
for the duration of MJS (see online supplementary
ﬁgure S1).
Functional Assessment of Chronic Illness Therapy-Fatigue
Treatment with baricitinib 4 mg was associated with sig-
niﬁcant improvement in FACIT-F at week 24 (ﬁgure 1).
The improvements in the FACIT-F score were observed
at week 4, the ﬁrst assessment of the measure (ﬁgure 1).
Table 1 Patient characteristics, disease activity and patient-reported outcomes at baseline
Placebo
(N=228)
Baricitinib 2 mg
(N=229)
Baricitinib 4 mg
(N=227)
Patient characteristics
Age, years 51.4 (13) 52.2 (12) 51.8 (12)
Female patients, n (%) 189 (83) 184 (80) 187 (82)
Duration of RA (time from symptom onset), years 7.2 (8) 7.6 (8) 7.7 (8)
Concomitant corticosteroid use, n (%) 114 (50) 117 (51) 115 (51)
Concomitant MTX use, n (%) 167 (73) 170 (74) 171 (75)
Mean (SD) MTX dose, mg/week 16 (5) 16 (5) 16 (5)
Number of prior csDMARDS, n (%)
1 96 (42) 104 (45) 98 (43)
2 81 (36) 61 (27) 68 (30)
≥3 50 (22) 61 (27) 60 (26)
Number of concomitant csDMARDs, n (%)
0 17 (8) 18 (8) 13 (6)
1 150 (66) 145 (63) 151 (67)
MTX 109 (48) 111 (49) 114 (50)
Non-MTX 41 (18) 34 (15) 37 (16)
2 55 (24) 58 (25) 57 (25)
MTX + non-MTX 52 (23) 51 (22) 51 (23)
2 non-MTX 3 (1) 7 (3) 6 (3)
≥3 6 (3) 8 (4) 6 (3)
Disease activity
Swollen joint count, of 66 13 (7) 14 (9) 14 (7)
Tender joint count, of 68 24 (15) 24 (14) 24 (14)
hsCRP, mg/L 18 (20) 18 (22) 14 (15)
ESR, mm/hour 44 (25) 44 (23) 41 (24)
DAS28-hsCRP 5.5 (0.9) 5.6 (1.0) 5.6 (0.9)
SDAI 37 (12) 38 (13) 38 (12)
CDAI 35 (12) 37 (13) 36 (12)
Patient-reported outcome measures
Health Assessment Questionnaire-Disability Index
(HAQ-DI, 0–3)
1.50 (0.60) 1.51 (0.62) 1.55 (0.60)
Patient’s Global Assessment of Disease
Activity (0–100 VAS)
60 (21) 62 (20) 60 (22)
Patient’s Assessment of Pain (0–100 VAS) 57 (23) 60 (21) 57 (22)
Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F, 0–52)
26.6 (11.1) 26.6 (11.5) 27.3 (11.1)
Short Form 36 (SF-36)
Physical component score (PCS) 32.2 (8.5) 32.5 (8.4) 32.2 (8.1)
Mental component score (MCS) 45.7 (11.5) 45.0 (11.5) 46.3 (12.3)
European Quality of Life-5 Dimensions-5 Level (EQ-5D)
Health State Index Score, UK algorithm 0.543 (0.214) 0.507 (0.249) 0.516 (0.236)
VAS (0–100) 51.6 (19.7) 53.1 (20.5) 52.8 (20.0)
Data displayed are mean (SD), unless otherwise stated.
CDAI, Clinical Disease Activity Index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS, Disease Activity
Score modified to include the 28 diarthrodial joint count; ESR, erythrocyte sedimentation rate; hsCRP, high-sensitivity C reactive protein; MTX,
methotrexate; SDAI, Simplified Disease Activity Index; VAS, visual analogue scale.
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Table 2 Day 1, week 1 and week 12 data from patient daily diaries
Diary PRO
measures
Day 1
Median (IQR)
Week 1
Median (IQR)
Week 12
Median (IQR)
Placebo
(N=228)
Baricitinib 2 mg
(N=229)
Baricitinib 4 mg
(N=227)
Placebo
(N=228)
Baricitinib 2 mg
(N=229)
Baricitinib 4 mg
(N=227)
Placebo
(N=228)
Baricitinib 2 mg
(N=229)
Baricitinib 4 mg
(N=227)
Duration of morning
joint stiffness, min
60.0
(30.0, 180.0)
80.0
(30.0, 180.0)
75.0
(30.0, 180.0)
84.0
(36.8, 195.0)
80.0
(36.7, 157.5)
80.0
(32.9, 188.6)
60.0
(22.9, 162.9)
44.4**
(9.1, 120.0)
34.6***
(7.4, 96.4)
Day 1
Mean (SD)
Week 1
LSM
(95% CI)
Week 12
LSM
(95% CI)
Severity of morning
joint stiffness
5.5 (2.1) 5.5 (2.1) 5.3 (2.1) 5.1
(5.0 to 5.3)
5.0
(4.8 to 5.2)
4.9*
(4.7 to 5.1)
4.1
(3.8 to 4.4)
3.5**
(3.2 to 3.8)
3.4***
(3.1 to 3.7)
Worst Tiredness 5.8 (2.0) 5.7 (2.3) 5.7 (2.2) 5.2
(5.0 to 5.4)
5.2
(5.0 to 5.4)
5.0
(4.9 to 5.2)
4.5
(4.2 to 4.8)
4.1*
(3.8 to 4.4)
4.0*
(3.7 to 4.4)
Worst Joint Pain 5.8 (2.0) 5.9 (2.2) 5.7 (2.0) 5.6
(5.4 to 5.8)
5.3
(5.2 to 5.5)
5.2**
(5.0 to 5.4)
4.7
(4.4 to 5.0)
3.8***
(3.5 to 4.1)
3.8***
(3.5 to 4.2)
*p≤0.05; **p≤0.01; ***p≤0.001.
LSM, least-squares mean.
Table 3 Least-squares mean change from baseline at 12 and 24 weeks for patient-reported outcomes
PRO measures
Week 12
LSM (95% CI)
Week 24
LSM (95% CI)
Placebo
(N=228)
Baricitinib 2 mg
(N=229)
Baricitinib 4 mg
(N=227)
Placebo
(N=228)
Baricitinib 2 mg
(N=229)
Baricitinib 4 mg
(N=227)
Physical function
(HAQ-DI)
−0.36
(−0.43 to −0.29)
−0.57***
(−0.64 to −0.50)
−0.56***
(−0.63 to −0.48)
−0.38
(−0.46 to −0.30)
−0.62***
(−0.70 to −0.54)
−0.62***
(−0.70 to −0.54)
Patient’s Global
Assessment of Disease
Activity (PtGA)
−16.8
(−20.0 to −13.6)
−25.3***
(−28.5 to −22.2)
−25.8***
(−29.1 to −22.6)
−18.8
(−22.0 to −15.6)
−27.6***
(−30.8 to −24.5)
−29.1***
(−32.4 to −25.9)
Patient’s Assessment of
Pain
−15.6
(−18.9 to −12.3)
−25.4***
(−28.6 to −22.2)
−23.4***
(−26.7 to −20.1)
−19.6
(−22.9 to −16.3)
−27.4***
(−30.6 to −24.2)
−27.9***
(−31.2 to −24.6)
EuroQol-5-Dimensions (EQ-5D-5L)
Health State Index Score
UK algorithm 0.092
(0.066 to 0.119)
0.165***
(0.139 to 0.191)
0.162***
(0.135 to 0.189)
0.091
(0.063 to 0.119)
0.157***
(0.130 to 0.184)
0.186***
(0.158 to 0.215)
US algorithm 0.066
(0.048 to 0.085)
0.117***
(0.099 to 0.135)
0.112***
(0.093 to 0.131)
0.062
(0.042 to 0.082)
0.111***
(0.092 to 0.130)
0.131***
(0.111 to 0.151)
VAS 4.5
(1.7 to 7.4)
13.5***
(10.7 to 16.2)
11.3***
(8.4 to 14.1)
7.9
(4.7 to 11.1)
13.9**
(10.8 to 17.0)
11.0
(7.8 to 14.2)
**p≤0.01, ***p≤0.001 vs placebo.
LSM, least-squares mean; VAS, visual analogue scale.
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Numeric improvements in FACIT-F were observed for
baricitinib 2 mg versus placebo, but a statistically signiﬁ-
cant improvement was only observed at week 20.
For FACIT-F, the proportion of patients who met or
exceeded the MCID was 59%, 63% and 65% for
placebo, baricitinib 2 mg and baricitinib 4 mg, respect-
ively, at week 12 (p=0.323 for baricitinib 2 mg vs placebo
and p=0.209 for baricitinib 4 mg vs placebo), and was
43%, 59% and 60% at week 24 (p=0.001 for both barici-
tinib groups vs placebo).
Health-related quality of life
Short Form 36
Patients treated with baricitinib 2 or 4 mg reported statis-
tically signiﬁcant improvements compared with placebo
in most of the 8 SF-36 domains at weeks 12 and 24.
The values for the social functioning, role emotional
and the mental health domains improved for the bariciti-
nib treatment groups, but differences from placebo were
not statistically signiﬁcant (see online supplementary
table S2).
Compared with placebo-treated patients, patients in
both baricitinib treatment groups reported statistically
signiﬁcantly improved values for the SF-36 PCS
(ﬁgure 2A), from the ﬁrst postbaseline assessment at
week 4 and maintained through week 24. At week 12,
the proportion of patients who met or exceeded the
MCID for placebo, baricitinib 2 mg and baricitinib 4 mg,
respectively, was 40%, 57% and 53% (p=0.001 for barici-
tinib 2 mg vs placebo; p=0.006 for baricitinib 4 mg vs
placebo) and was 34%, 56% and 56% at week 24
(p=0.001 for both baricitinib groups vs placebo). For the
SF-36 MCS measure, numeric, but not statistically signiﬁ-
cant, differences in the change from baseline were
found between the baricitinib-treated groups versus
placebo. The proportion of patients who met or
exceeded the MCID was not statistically signiﬁcantly
different from placebo for either baricitinib treatment
group (ﬁgure 2B).
EuroQol 5-Dimensions
At weeks 12 and 24, statistically signiﬁcant improvement
in the EQ-5D UK index score was observed for both bari-
citinib treatment groups versus placebo (table 3). A stat-
istically signiﬁcant improvement in the EQ-5D UK index
score was observed at the ﬁrst postbaseline assessment,
week 4, for baricitinib 4 mg versus placebo, but not for
baricitinib 2 mg versus placebo (data not shown).
For the EQ-5D VAS, at week 12, statistically signiﬁcant
improvement in the EQ-5D VAS was observed for both
baricitinib treatment groups versus placebo (p=0.001 for
both baricitinib groups vs placebo); this was maintained
through week 24 for the 2 mg group (p=0.005 vs
placebo) but not for the 4 mg group (p=0.159 vs
placebo) (table 3). Baricitinib-treated patients were not
signiﬁcantly different from placebo-treated patients at
week 4, the ﬁrst data assessment (data not shown).
Similar results were observed with the US algorithm for
the EQ-5D (table 3).
Work productivity and activity impairment
At baseline, only 34–40% of the patients were employed
(table 4). Patients treated with baricitinib 2 or 4 mg
reported statistically signiﬁcantly improved regular activ-
ity compared with placebo-treated patients at week 12
(p=0.004 for baricitinib 2 mg vs placebo and p=0.003 for
baricitinib 4 mg vs placebo) but not at week 24 for
either group (p=0.156 for baricitinib 2 mg vs placebo
and p=0.179 for baricitinib 4 mg vs placebo; table 4).
Among those patients who were employed at baseline
and those who maintained employment at weeks 12 or
24, statistically signiﬁcant improvements with respect to
presenteeism for baricitinib 2 mg and work productivity
loss for baricitinib 2 mg and 4 mg were seen compared
Figure 1 Change from baseline
for Functional Assessment of
Chronic Illness Therapy-Fatigue.
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with placebo at week 12 but not at week 24 (table 4). No
statistically signiﬁcant differences between groups were
seen for absenteeism.
DISCUSSION
In this analysis of the Phase III RA-BUILD trial, baseline
PROs revealed long duration (∼90 min) and severity of
MJS, severe impairment of physical function and high
levels of pain and fatigue (including tiredness) among
patients with RA and an IR to csDMARDs, who had not
previously been treated with a biological DMARD.
Once-daily baricitinib 2 or 4 mg produced signiﬁcant
improvements compared with placebo in most of the
prespeciﬁed PROs, including physical function, fatigue,
duration and severity of MJS, pain and HRQOL. For
some PROs, including selected daily diary measures,
treatment with the 4 mg dose resulted in more rapid
improvement compared with the 2 mg dose.
The PROs demonstrated a rapid onset of action for
baricitinib; statistically signiﬁcant improvements were
seen as early as week 1 in the HAQ-DI, PtGA and the
patient assessment of pain, and were maintained until
the end of the trial at week 24. Similar results were seen
with severity of MJS, Worst Tiredness, Worst Joint Pain as
assessed using the patient diaries,18 and the PROs con-
tinued to improve to week 12. Consistent with these
results, patients treated with baricitinib 2 or 4 mg
reported greater improvement in HRQOL, as measured
by the EQ-5D and SF-36 PCS, compared with placebo-
treated patients. For the SF-36 component scores, a
change from baseline of either 2.5 or 5 is typically con-
sidered an MCID.27 28 This analysis applied the higher
threshold for the MCID and found that approximately
Figure 2 Change from baseline
for the physical and mental
component score for the SF-36.
(A) Physical component score.
(B) Mental component score.
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half of the baricitinib-treated patients reported scores
that met or exceeded the MCID for the SF-36 PCS
(ﬁgure 2A). In contrast with the SF-36 PCS, no statistic-
ally signiﬁcant differences were observed between
baricitinib-treated and placebo-treated patients with the
SF-36 MCS. Across treatment groups at baseline, the
SF-36 MCS values ranged from 45 to 46, which are close
to 50, the population norm.27 This suggests limited
impairment for the SF-36 MCS at baseline; consequently,
a marked improvement with therapy would not have
been expected. The SF-36 MCS result aligns with previ-
ous results from other trials of baricitinib.34–36
The WPAI-RA data are difﬁcult to interpret, as the
number of patients who were employed at baseline and
employed throughout the trial was small, and the
24-week duration is most likely a relevant limitation for
this measure. A study with a longer duration and a focus
on work productivity may provide more deﬁnitive evi-
dence regarding the potential treatment effects of barici-
tinib on work productivity.
The results from this analysis are similar to those
observed in three other phase III randomised clinical
trials of baricitinib in different patient populations.34–36
Additionally, the improvements in the PROs with barici-
tinib in the current analysis were directionally consistent
with the results reported with approved biological or tar-
geted synthetic DMARD therapies in analogous patient
populations.37–40
The limitations of this analysis include the use of car-
rying forward the last observations before rescue or dis-
continuation as a method of imputation for some
continuous measures. Although an appropriate method
of handling such data, this method assumes that the
PRO values would not change over time if these events
had not occurred, an unveriﬁable assumption. Most
patients (89%), however, completed the trial;18 sensitiv-
ity analyses assessing missing data (data not shown)
suggest that the study results would not be inﬂuenced by
this data handling method. Additionally, this is a short-
term study of 24 weeks, which does not allow for an
assessment of the long-term treatment effects of
baricitinib. This may particularly affect work productivity
assessments. The employment status of patients in this
study did not improve signiﬁcantly, most likely because
of the short duration of the trial; patients with
disease-associated unemployment are unlikely to recover,
then search for and ﬁnd new work within 6 months.
Furthermore, patients from 22 countries participated in
the trial; the different rates of unemployment and pol-
icies related to workplace accommodations for RA may
have inﬂuenced a patient’s employment status.
This study has used a number of established PRO
measures that assess outcomes of interest for patients.
Some measures are incorporated in the ACR core set
measures, and others, such as the EQ-5D and SF-36, are
commonly used HRQOL instruments that may more
broadly assess the effects of RA and its treatment on
patients. Information from PROs may help the
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healthcare provider and patient determine the optimal
treatment plan for the patient by (1) identifying the
onset of action for when the patient will feel an improve-
ment in symptoms, (2) evaluating the length of time the
patient should try the treatment before determining
that it is ineffective and (3) assessing if the treatment is
still efﬁcacious after initial improvement. Observing posi-
tive changes in PROs may help the patient adhere to
therapy, an important element of treatment effective-
ness. Additionally, the inclusion of PRO measures in
clinical trials also helps to compare results across studies
and patient populations and to assess the broader soci-
etal impact of RA and treatment for it.
In conclusion, the RA-BUILD study demonstrated that
treatment with baricitinib 2 or 4 mg provided a signiﬁ-
cant improvement compared with placebo in most PROs
across different domains of RA, including physical func-
tion, MJS, fatigue, pain and HRQOL. Improvements
tended to occur rapidly, most notably for the 4 mg dose,
and were maintained throughout the 24-week trial.
These results conﬁrm that the efﬁcacy of baricitinib is
not limited to physician-based or laboratory-based assess-
ments, but that efﬁcacy translates to a positive beneﬁt on
patients’ quality of life and overall function. Consistent
with prior observations, these data support a conclusion
that baricitinib is a potentially valuable addition to the
RA treatment arsenal for patients struggling with this
common and disabling condition.
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